Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK105 + anlotinib + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination consists of four anticancer agents: - **AK105** is an anti-PD-1 monoclonal antibody (immune checkpoint inhibitor) designed to block programmed death-1 (PD-1) pathway, enhancing T cell-mediated immune responses against tumors. - **Anlotinib** is an oral multi-targeted tyrosine kinase inhibitor that affects angiogenesis and tumor cell proliferation by inhibiting vascular endothelial growth factor receptors (VEGFR1/2/3), platelet-derived growth factor receptors (PDGFRα/β), fibroblast growth factor receptors (FGFR1-4), c-Kit, and MET[1][3][5]. - **Capecitabine** is an oral prodrug of 5-fluorouracil (5-FU), a cytotoxic antimetabolite interfering with DNA synthesis in rapidly dividing cells[2][6]. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis of cancer cells[2][6]. The combination brings together immunotherapy (AK105), anti-angiogenic targeted therapy (anlotinib), and cytotoxic chemotherapy (capecitabine, oxaliplatin) for synergistic antitumor effects. It is under clinical investigation for treatment of various advanced malignancies, most notably colorectal cancer and other gastrointestinal tumors.
- Brand names
- XELOXCAPOX
- Other names
- AK105 + anlotinib + capecitabine + oxaliplatin
02
Targets
TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on AK105 + anlotinib + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK105 + anlotinib + capecitabine + oxaliplatin.